Anti Cold « Go Back
  • MYTIFLOX
  • DEFTOLIDE
  • E-MYCIN
  • Qualitative & Quantitative Composition.

    Each film coated tablet contains Levofloxacin I.P. 500 mg
  • Dosage Form

    Oral Tablets
  • Therapeutic indications

    Respiratory tract infections
    Urinary tract infections
    Tuberculosis
    Typhoid
  • Dosage and administration

    1 tablet once or twice daily. The dosage depends on the type and severity of the infection and the susceptibility of the presumed causative pathogen.
    As directed by physician
  • Contra-indications

    Should not use if allergic to levofloxacin or other quinolones or any of the other ingredients in the product.
    Also contraindicated in epileptic patients and during pregnancy .
  • Warnings and Precautions

    While generally safe for use at recommended doses acute overdoses of levofloxacin can cause increase in tendon rupture and hematologic changes including thrombocytopenia and agranulocytosis. fatal liver damage and, in rare individuals, a normal dose can do the same; the risk is heightened by alcohol consumption. Levofloxacin may also effects Central nervous system and may cause convulsions, anxiety, confusion, depression, and insomnia after the first dose.
  • Drug interactions

    Increased concentration of ciclosporin or tacrolimus. Reduced absorption with didanosine, ferrous sulfate or dietary supplements containing zinc, calcium, magnesium or iron. May increase plasma levels of theophylline. Increased risk of tendon rupture with corticosteroids. Reduced absorption with sucralfate and antacids containing magnesium and aluminium; administer at least 2 hr before or 2 hr after antacids. Increased half-life and decreased clearance of procainamide. Altered glucose levels with antidiabetic agents (e.g. insulin, glyburide).
    Potentially Fatal: Increased risks of ventricular arrhythmias with QT prolonging drugs e.g. class IA (quinidine, procainamide) or class III (amiodarone, sotalol) antiarrhythmics, fluoxetine, imipramine. Increased risk of CNS stimulation and seizures with NSAIDs. Increased prothrombin time with warfarin.
  • Pregnancy & lactation

    Category C.
  • Undesirable effects/side effects

    Levofloxacin is generally well tolerated. The most common adverse effects are nausea, diarrohea, abdominal pain, constipation, dizziness, headache, and vaginitis in women.
    Pain swelling, and tears of shoulder, hand or Achilles of tendons have been reported and effects on tendons are sever. Levofloxacin may also cause convulsions and CNS related adverse effects like tremors, restlessness, anxiety, lightheadedness, confusion, hallucinations, depression, insomnia and rarely suicidal thoughts. Sun sensitivity is also associated with levofloxacin.
  • Overdose

    Most important signs to be expected following acute overdose of levofloxacin tablets are central nervous system symptoms such as confusion, dizziness, impairment of consciousness and convulsive seizures, increases in QT interval as well as gastro-intestinal reactions such as nausea and mucosal erosions.
  • Qualitative & Quantitative Composition.

    Each film coated tablet contains Azithromycin dihydrate I.P. equivalent to Azithromycin (Anhydrous) 250mg / 500mg.
    Each 5 ml contains Azithromycin dihydrate I.P. equivalent to Azithromycin (Anhydrous) 100mg / 200mg.
    In flavored base.
    Colour: Quinoline yellow
  • Dosage Form

    Oral Tablets
    Oral Suspension
  • Therapeutic indications

    Respiratory tract infections
    Skin and soft tissue infections
    Urinary tract infections
    Sexually transmitted diseases
    Typhoid
    Malaria
  • Dosage and administration

    Deftolide 250mg Tablet: 500 mg as a single dose on the 1st day followed by 250 mg once daily for 4 days.
    Deftolide 500mg Tablet: 500 mg once daily for 3 days.
    Deftolide 100mg and 200mg Suspension:
    • • 3 Days therapy: Day 1 to 3 - 10 mg/kg/day
    • • 5 Days therapy: Day 1 - 10 mg/kg/day and Day 2 to 5 – 5mg/kg/day
    As directed by physician
  • Contra-indications

    Hypersensitivity.
  • Warnings and Precautions

    Impaired liver and renal function; pregnancy and lactation; children.
  • Drug interactions

    Antacids containing aluminium and magnesium salts reduce rate of absorption. Increased risk of ergot toxicity. Potentially Fatal: Increased serum concentrations of digoxin and ciclosporin.
  • Pregnancy & lactation

    Category B
  • Undesirable effects/side effects

    Mild to moderate nausea, vomiting, abdominal pain, dyspepsia, flatulence, diarrhoea, cramping; angioedema, cholestatic jaundice; dizziness, headache, vertigo, somnolence; transient elevations of liver enzyme values.
  • Overdose

    Adverse events experienced in higher than recommended doses were similar to those seen at normal doses. The typical symptoms of an overdose with macrolid antibiotics include reversible loss of hearing, severe nausea, vomiting and diarrhoea. In the event of overdose, general symptomatic and supportive measures are indicated as required.
  • Qualitative & Quantitative Composition.

    Each uncoated tablet contains Erythromycin estolate equivalent to Erythromycin U.S.P. 250 mg.
    Each 5ml contains Erythromycin Estolate equivalent to Erythromycin U.S.P. 125 mg.
    In flavored syrup base.
    Colour: Sunset Yellow FCF.
  • Dosage Form

    Oral Tablets
    Oral Suspension
  • Therapeutic indications

    Respiratory tract infections
    Skin and soft tissue infections
    Urinary tract infections
  • Dosage and administration

    Adults and children over 8 years: 2g/day in divided doses. For severe infections up to 4g/day in divided doses. Children 2 - 8 years: 30 mg/kg/day in divided doses. For severe infections up to 50 mg/kg/day in divided doses.
    Normal dose: 250mg four times a day or 500mg twice daily.
    Children up to 2 years: 30 mg/kg/day in divided doses. For severe infections up to 50 mg/kg/day in divided doses.
    Normal dose: 125mg four times a day or 250mg twice daily.
    As directed by physician
  • Contra-indications

    Hypersensitivity; porphyria; hepatic impairment; pregnancy
  • Warnings and Precautions

    Increased risk of cholestatic hepatitis when treatment is >10 days or in patients with previous history of erythromycin usage. History of hepatic disorders; arrhythmias; prolonged QT interval; lactation. Monitor liver function. Avoid estolate in liver impairment. Caution when using lactobionate in patients with severe renal impairment. May aggravate muscle weakness in patients with myasthenia gravis.
  • Drug interactions

    May antagonise therapeutic effects lincomycin and clindamycin. Concurrent usage may lead to increased absorption of alcohol. Potentially Fatal: May antagonise therapeutic effects lincomycin and clindamycin. Concurrent usage may lead to increased absorption of alcohol.
  • Pregnancy & lactation

    Category B.
  • Undesirable effects/side effects

    Rash, urticaria; nausea, vomiting, GI discomfort; ototoxicity; central neurotoxicity; agranulocytosis; arrhythmias; pancreatitis.
    Potentially Fatal: Hepatotoxicity, cholestatic jaundice; raised serum transaminases; eosinophilia.
  • Overdose

    Overdosage may cause hearing loss, severe nausea, vomiting and diarrhoea.